Luca Bolliger studied biochemistry at the ETH in Zürich and completed his undergraduate studies with a Master in Immunology. He graduated at the Biocenter in Basel in biochemistry, and then became Member of the Basel institute for immunology. He then joined the pharmaceutical industry as a Global discovery portfolio manager in the Pharma Strategy Unit at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental analyst at BT&T asset management, and as a freelance consultant. He established Biopolo Ticino where he also participated in the creation of the Swiss marketing platforms Swiss Biotech and Swiss Medtech before becoming Director Business Development at Actelion. Luca Bolliger joined Recordati from Novimmune where he was director Business Development. In his last position as VP Corporate Licensing Luca was looking for assets in the space of primary-specialty care with a particular attention to the orphan space, but also overlooking a number of alliances.
Interests: disruptive innovation and arts